Voyager Therapeutics Inc. (VYGR)
NASDAQ:VYGR
Want to see VYGR full AI Analyst Report?
Total Valuation
Voyager Therapeutics has a market cap or net worth of $211.47M. The enterprise value is $202.73M.
Market Cap$211.47M
Enterprise Value$202.73M
Share Statistics
Voyager Therapeutics has 60,421,288 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding60,421,288
Owned by Insiders2.21%
Owned by Institutions19.12%
Financial Efficiency
Voyager Therapeutics’s return on equity (ROE) is -0.61 and return on invested capital (ROIC) is -56.44%.
Return on Equity (ROE)-0.61
Return on Assets (ROA)-0.47
Return on Invested Capital (ROIC)-56.44%
Return on Capital Employed (ROCE)-0.58
Revenue Per Employee234.73K
Profits Per Employee-696.05K
Employee Count172
Asset Turnover0.16
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Voyager Therapeutics is ―. Voyager Therapeutics’s PEG ratio is -0.02.
PE Ratio―
PS Ratio5.71
PB Ratio1.18
Price to Fair Value1.18
Price to FCF-1.71
Price to Operating Cash Flow-1.63
PEG Ratio-0.02
Income Statement
In the last 12 months, Voyager Therapeutics had revenue of 40.37M and earned -119.72M in profits. Earnings per share was -2.04.
Revenue40.37M
Gross Profit40.37M
Operating Income-131.84M
Pretax Income-119.58M
Net Income-119.72M
EBITDA-127.78M
Earnings Per Share (EPS)-2.04
Cash Flow
In the last 12 months, operating cash flow was -127.99M and capital expenditures -1.95M, giving a free cash flow of -129.94M billion.
Operating Cash Flow-127.99M
Free Cash Flow-129.94M
Free Cash Flow per Share-2.15
Dividends & Yields
Voyager Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.23
52-Week Price Change11.11%
50-Day Moving Average3.97
200-Day Moving Average4.07
Relative Strength Index (RSI)37.24
Average Volume (3m)538.68K
Important Dates
Voyager Therapeutics upcoming earnings date is Jul 30, 2026, TBA (Confirmed).
Last Earnings DateMay 7, 2026
Next Earnings DateJul 30, 2026
Ex-Dividend Date―
Financial Position
Voyager Therapeutics as a current ratio of 7.64, with Debt / Equity ratio of 19.90%
Current Ratio7.64
Quick Ratio7.64
Debt to Market Cap0.03
Net Debt to EBITDA0.23
Interest Coverage Ratio0.00
Taxes
In the past 12 months, Voyager Therapeutics has paid 144.00K in taxes.
Income Tax144.00K
Effective Tax Rate>-0.01
Enterprise Valuation
Voyager Therapeutics EV to EBITDA ratio is -1.58, with an EV/FCF ratio of -1.49.
EV to Sales5.00
EV to EBITDA-1.58
EV to Free Cash Flow-1.49
EV to Operating Cash Flow-1.52
Balance Sheet
Voyager Therapeutics has $141.48M in cash and marketable securities with $34.57M in debt, giving a net cash position of $106.91M billion.
Cash & Marketable Securities$141.48M
Total Debt$34.57M
Net Cash$106.91M
Net Cash Per Share$1.77
Tangible Book Value Per Share$3.34
Margins
Gross margin is 97.45%, with operating margin of -326.56%, and net profit margin of -296.53%.
Gross Margin97.45%
Operating Margin-326.56%
Pretax Margin-296.17%
Net Profit Margin-296.53%
EBITDA Margin-316.50%
EBIT Margin-326.56%
Analyst Forecast
The average price target for Voyager Therapeutics is $15.14, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price Target$15.14
Price Target Upside266.66% Upside
Analyst ConsensusStrong Buy
Analyst Count9
Revenue Growth Forecast-45.50%
EPS Growth Forecast-35.63%